Novavax: co-exclusive licensing agreement with Sanofi
Novavax will receive an upfront payment of $500 million, rising to $700 million depending on the achievement of various milestones, and tiered double-digit royalties on Sanofi sales of Covid-19 and influenza-Covid-19 vaccines.
Novavax will also be entitled to payments of up to $200 million, as well as single-digit royalties for each additional Sanofi vaccine developed under non-exclusive license with Novavax's Matrix-M adjuvant technology.
'Outside of this collaboration, each party will be able to develop and commercialize, at its own expense, its own influenza and Covid-19 vaccines, as well as its own adjuvanted products', says the French healthcare group.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction